2,3-dihydro-2-methyl-1,4-benzodioxin-2-methyl 4-tolylsulfonate | 16163-78-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-dihydro-2-methyl-1,4-benzodioxin-2-methyl 4-tolylsulfonate
• 英文别名: 2-Methyl-2-tosyloxymethyl-1,4-benzodioxan；2,3-dihydro-2-methyl-2-tosyloxymethyl-1,4-benzodioxin；(3-methyl-2H-1,4-benzodioxin-3-yl)methyl 4-methylbenzenesulfonate
• CAS: 16163-78-3
• 化学式: C₁₇H₁₈O₅S
• 分子量: 334.393
• InChiKey: OUKLGVNVWONEEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-2-methyl-1,4-benzodioxin-2-methyl 4-tolylsulfonate 在 氢氧化钾 作用下， 以 叔丁醇 为溶剂， 反应 5.0h， 以54%的产率得到2-hydroxymethyl-2-methyl-2,3-dihydro-1,4-benzodioxin
  参考文献：
  名称：

  （2-烷基-1,4-苯并二恶烷-2-基）羧酸作为潜在的降血脂药

  摘要：

  1，2-二酚与2-烷基-3-氯-1，2-环氧丙烷反应，得到1，4-苯并二恶烷V和1，5-苯并二氧杂庚烷VII的醇的混合物。由高锰酸钾氧化苯并二恶烷化合物V，得到相应的（2-烷基-1，4-苯并二恶烷-2-基）羧酸II。在初步的药理学评估中，苯并二恶烷酸II对血浆胆固醇没有显示任何影响，同时会导致甘油三酸酯的适度降低。

  DOI：

  10.1002/jhet.5570170313
• 作为产物：
  描述：

  2-hydroxymethyl-2-methyl-2,3-dihydro-1,4-benzodioxin 以86%的产率得到
  参考文献：
  名称：

  SALIMBENI A.; MANGHISI E., J. HETEROCYCL. CHEM., 1980, 17, NO 3, 489-492

  摘要：

  DOI：

文献信息

• 2,2-disubstitued 2,3-dihydro-1,4-benzodioxin derivatives having
  申请人：Istituto Luso Farmaco d'Italia S.p.A.

  公开号：US04948797A1

  公开（公告）日：1990-08-14

  2,2-Disubstituted 2,3-dihydro-1,4-benzodioxin derivatives of formula (I): ##STR1## and pharmaceutically acceptable salts thereof having in vitro high affinity and selectively for .alpha..sub.1 receptors and in vivo good and long lasting hypotensive activty, with negligible side-effects; processes for the preparation thereof and pharmaceutical compositions therefrom.

  式(I)的2,2-二取代2,3-二氢-1,4-苯并二氧杂环己烷衍生物：##STR1##及其药学上可接受的盐具有体外对α1受体高亲和力和选择性，体内具有良好且持久的降压活性，副作用极小；其制备方法和由此制备的药物组合物。
• 2,2-Disubstituted 2,3-dihydro-1,4-benzodioxin derivatives having hypotensive activity
  申请人：ISTITUTO LUSO FARMACO D'ITALIA S.p.A.

  公开号：EP0367888A1

  公开（公告）日：1990-05-16

  2,2-Disubstituted 2,3-dihydro-1,4-benzodioxin de­rivatives of formula (I): and pharmaceutically acceptable salts thereof having in vitro high affinity and selectivity for α₁ receptors and in vivo good and long lasting hypotensive activity, with negligeable side-effects; processes for the preparation thereof and pharmaceutical compositions therefrom.

  公式（I）的2,2-二取代2,3-二氢-1,4-苯并二氧杂环己烷衍生物及其药学上可接受的盐具有体外对α₁受体的高亲和力和选择性以及体内良好且持久的降压活性，且副作用可忽略；其制备方法以及由此制备的药物组合物。
• <i>N</i>-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D₂ Antagonists/5-HT_1A Partial Agonists with Potential as Atypical Antipsychotic Agents
  作者：Alan M. Birch、Paul A. Bradley、Julie C. Gill、Frank Kerrigan、Pat L. Needham

  DOI：10.1021/jm9910122

  日期：1999.8.1

  A series of N-substituted 1-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives with D-2 antagonist/5-HT1A partial agonist activity has been prepared as potential atypical antipsychotic agents. Optimization of in vitro receptor binding activity and in vivo activity in rodent models of psychosis has led to compound 24, which showed good affinities for human D-2, D-3, and 5-HT1A receptors but significantly less affinity for human alpha(1) adrenoceptors and rat H-1 and muscarinic receptors. In rodents, 24 showed functional D-2-like antagonism and 5-HT1A partial agonism. After oral dosing, 24 showed good activity in rodent antipsychotic tests and very little potential to cause extrapyramidal side effects (EPS), as measured by its ability to induce catalepsy in rats only at very high doses. In the light of this promising profile of activity, 24 has been selected for clinical investigation as a novel antipsychotic agent with a predicted low propensity to cause EPS.
• Salimbeni; Manghisi; Ferni, Farmaco, Edizione Scientifica, 1983, vol. 38, # 8, p. 571 - 583
  作者：Salimbeni、Manghisi、Ferni、Fregnan

  DOI：——

  日期：——
• Salimbeni, Aldo; Manghisi, Elso; Arnone, Alberto, Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 943 - 947
  作者：Salimbeni, Aldo、Manghisi, Elso、Arnone, Alberto

  DOI：——

  日期：——